<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854786</url>
  </required_header>
  <id_info>
    <org_study_id>EB/181201/OXYJUN/EVRG</org_study_id>
    <nct_id>NCT03854786</nct_id>
  </id_info>
  <brief_title>Aerobic Fitness in Overweight and Obese Individuals</brief_title>
  <official_title>A Randomized, Placebo-controlled, Multi-blind Study to Assess the Effect of Oxyjun on Aerobic Fitness in Overweight and Obese Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxyjun is known for improving cardiovascular endurance. Overweight and obese individuals are
      at increased risk of cardiovascular complications. To lower the risk, these individuals need
      to remain physically active with acceptable aerobic fitness.

      Hence, the objective of the study is to investigate the effect of Oxyjun on aerobic fitness
      in physically active overweight and obese individuals. All subjects in the study will be
      tested for maximum aerobic capacity , body composition, and serum biomarker for fitness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the effect on Oxyjun on aerobic fitness in overweight and obese individuals</measure>
    <time_frame>From baseline to Day 56</time_frame>
    <description>Measured by change in VO2 max</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oxyjun</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxyjun- 400 mg OD after breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methyl Crystalline Cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Methyl Crystalline Cellulose- 400 mg OD after breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oxyjun</intervention_name>
    <description>Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.</description>
    <arm_group_label>Oxyjun</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pacebo</intervention_name>
    <description>Methyl Crystalline Cellulose</description>
    <arm_group_label>Methyl Crystalline Cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index ≥ 25 - ≤ 34.9 kg/m2.

          -  Waist Circumference ≥ 80 cms.

          -  Non-smoker.

          -  BP ≤ 140/90 mm Hg

          -  FBS ≤ 125 mg/dl

          -  Hb ≥ 11 g/ dl

          -  Can abstain from strenuous exercise and alcohol for at least 48 hours.

          -  Can abstain from caffeine for at least 24 hours.

        Exclusion Criteria:

          -  Participants with history of regular (≥2 times a week) structured exercise (gym,
             walking, yoga, etc).

          -  Inter-arm blood pressure is ≥10 mm Hg.

          -  Known cases of type II Diabetes Mellitus.

          -  Known cases of hypertension with or without anti-hypertensive medication.

          -  Visual or balance problems, or who cannot walk on a treadmill without using the
             handrails.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Sonal Raote, BAMS</last_name>
    <phone>9769323216</phone>
    <phone_ext>324</phone_ext>
    <email>sonal.raote@vediclifesciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vedic Lifesciences Pvt. Ltd</name>
      <address>
        <city>Mumbai</city>
        <state>Opp Infinity Mall</state>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hetal Mange, BAMS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

